openPR Logo
Press release

Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022

07-07-2017 08:59 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook

Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways of immune system which needs to respond against the HIV infection.

Vaccines are among the most powerful and cost-effective disease prevention tools. A vaccine that could prevent the HIV infection or stop the development of the disease would greatly support in the fight against the AIDS disease. Vaccines have been crucial in worldwide smallpox elimination efforts, have nearly eliminated polio and have drastically reduced the incidence of infectious diseases like measles and pertussis in the US.

However, the question is arising that whether HIV vaccine should be developed for a single strain or it should be designed for varied strain structures. The whole aim is to provide the better medication for the eradication of the virus by any means. There are also questions about how an HIV vaccine would protect the individuals and the vaccine might not be able to actually prevent the infection, but could stop or delay progression to disease, or simply reduce the infectiousness of people who do become infected with HIV. HIV prevention education and counseling are important constituents of vaccine programs and after the release of a vaccine; there will be an ongoing need for effective behavioral prevention programs.

The development of HIV vaccine will play an extremely powerful role for the prevention against the HIV infection. Now the researchers have a better understanding of the challenges which need to be solved to get an HIV vaccine. They knew the reasons of failure of prior vaccines and the trials provide the clue of neutralizing the antibodies which could protect the patients and now they know what they need to do.

For Report Sample Contact: or +91-11-47067990

Download Report:

Report Table of Contents

Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine

Need for the Development of HIV Vaccine

Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus

HIV Vaccine Development Process
4.1 Introduction
4.1.1 Classification of HIV Virus
4.1.2 Structure of HIV Virus
4.2 HIV Vaccine Construct Methodologies
4.2.1 Live Attenuated Vaccine
4.2.2 Synthetic Peptide Vaccines
4.2.3 Inactivated Vaccines
4.2.4 DNA Vaccine
4.2.5 Recombinant Vector Vaccine

Modified Approaches for HIV Vaccine Development
5.1 HIV Vaccine Expansion by Computer Aided Drug Design
5.2 Genetic Variety Attentions for Vaccine Design
5.3 Virus like Particles Approach for the HIV Vaccine Production
5.4 T-cell based Approach for HIV Vaccine

Prophylactic and Therapeutic HIV Vaccine
6.1 Prophylactic HIV Vaccine
6.1.1 Pre Exposure Prophylaxis
6.1.2 Post Exposure Prophylaxis (PEP)
6.2 Therapeutic HIV Vaccine

HIV Drugs Taxonomy and Resistance
7.1 Categorization of the Drugs
7.1.1 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs)
7.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
7.1.3 Protease Inhibitors
7.1.4 Fusion Inhibitors
7.2 Contrivance of HIV Drug Resistance
7.2.1 Resistance to Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
7.2.2 Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors
7.2.3 Resistance to Protease Inhibitors
7.2.4 Resistance to Fusion Inhibitors

Decisive Factors for Commercialization of HIV Vaccines
8.1 Efficacy
8.2 Controlled Transmission
8.3 Relapse
8.4 Economical
8.5 Manufacturing Scalability

Global HIV Vaccine Market Outlook
9.1 Overview
9.2 Current Market Scenario
9.3 Incidence and Prevalence
9.4 Funding Scenario for HIV Vaccine

Global HIV Vaccine Clinical Pipeline Overview

Global HIV Vaccine Market Dynamics
11.1 Favorable Market Parameters
11.2 Commercialization Challenges

Global HIV Vaccine Market Future Outlook

Global HIV Vaccine Clinical Pipeline by Company, Indication and Phase
13.1 Research
13.2 Preclinical
13.3 Clinical
13.4 Phase-I
13.5 Phase-I/II
13.6 Phase-II
13.7 Phase-III
13.8 Preregistration

Competitive Landscape
14.1 AlphaVax
14.2 Antigen Express
14.3 Argo Therapeutics
14.4 Bionor Pharmaceuticals
14.5 Celldex Therapeutics
14.6 FIT Biotech
14.7 Crucell Pharmaceutical
14.8 GeneCure
14.9 Genetic Immunity
14.10 GenVec
14.11 GeoVax Labs
14.12 Glaxo Smithkline
14.13 Immune Response BioPharma
14.14 Inovio Pharmaceuticals
14.15 Novartis
14.16 Oncolys Biopharma
14.17 PaxVax
14.18 Profectus Biosciences
14.19 Sanofi
14.20 TVAX Biomedical

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022 here

News-ID: 613366 • Views: 862

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases